Press Releases

Date Title and Summary View
Toggle Summary Revance Secures $8 Million in New Financing
Revance Secures $8 Million in New Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt Vice President, Marketing & Business Development (510) 742-3400 Newark, Calif. November 18, 2008 — Revance Therapeutics, Inc. (“Revance”) today announced an agreement with Leader Ventures and Horizon
View HTML
Toggle Summary Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a
View HTML
Toggle Summary Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin
CONTACT: Medicis Pharmaceutical Corporation Kara Stancell Executive Director, Investor Relations & Corporate Communications (480) 291-5854 Revance Therapeutics, Inc. Niquette Hunt Senior Vice President, Commercial Development (510) 742-3464 SCOTTSDALE, Ariz. and NEWARK, Calif.
View HTML
Toggle Summary Revance Annouces Series D Financing
Revance Annouces Series D Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – January 4, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing.
View HTML
Toggle Summary Revance Therapeutics Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society of Dermatologic Surgery
Revance Therapeutics Announces Clinical Trial Results of RT001 Topical Gel Presented at the Annual Meeting of the American Society of Dermatologic Surgery CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.
View HTML
Toggle Summary Revance Announces $45 Million Financing
Revance Announces $45 Million Financing CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures
View HTML
Toggle Summary Revance Therapeutics Regains All Worldwide Rights To Its Botulinum Toxin Products
Revance Therapeutics Regains All Worldwide Rights To Its Botulinum Toxin Products CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.—October 8, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination
View HTML
Toggle Summary Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
CONTACT: Revance Therapeutics, Inc. Niquette L. Hunt Senior Vice President, Commercial Development NEWARK, California—March 25, 2013 — Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate
View HTML
Toggle Summary Revance Therapeutics Announces $33 Million Series E Financing
CONTACT: Lauren Silvernail Chief Financial Officer and EVP Corporate Development 510-742-3415 lsilvernail@revance.com NEWARK, California — April 2, 2013 — Revance Therapeutics, Inc. (Revance), a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in
View HTML
Toggle Summary Revance Therapeutics Announces Pricing of Initial Public Offering
NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools